Glial dysfunction in the pathogenesis of α-synucleinopathies: Emerging concepts

Acta Neuropathologica

Volumn 121, Issue 6, 2011, Pages 675-693

  Fellner, Lisa ^a   Jellinger, Kurt A ^b   Wenning, Gregor K ^a   Stefanova, Nadia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Synuclein; Astroglia; Microglia; Multiple system atrophy; Neurodegeneration; Oligodendroglia; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AQUAPORIN 4; BRAIN DERIVED NEUROTROPHIC FACTOR; ENZYME INHIBITOR; EXCITATORY AMINO ACID TRANSPORTER 1; GANGLIOSIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MINOCYCLINE; NALOXONE; NEURTURIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; REACTIVE OXYGEN METABOLITE; SYNUCLEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VESICULAR GLUTAMATE TRANSPORTER 1;

ACTIVE IMMUNIZATION; AGING; ASTROCYTE; ASTROCYTOSIS; CELL FUNCTION; CELL INTERACTION; CELL LOSS; CLINICAL EFFECTIVENESS; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG TARGETING; GLIOSIS; HUMAN; MICROGLIA; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SHY DRAGER SYNDROME; VIRAL GENE DELIVERY SYSTEM;

ALPHA-SYNUCLEIN; GLIOSIS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROGLIA; NEURONS;

EID: 79958091447     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-011-0833-z     Document Type: Review

References (264)

1. Abeliovich A, Schmitz Y, Farinas I et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252 (Pubitemid 30316525)
2. Akira S (2001) Toll-like receptors and innate immunity. Adv Immunol 78:1-56
3. Al-Chalabi A, Durr A, Wood NW et al (2009) Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 4:e7114
4. Albert M (1993) Neuropsychological and neurophysiological changes in healthy adult humans across the age range. Neurobiol Aging 14:623-625
5. Amiry-Moghaddam M, Otsuka T, Hurn PD et al (2003) An alpha-syntrophin- dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc Natl Acad Sci USA 100:2106-2111 (Pubitemid 36254581)
6. Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739-29752 (Pubitemid 44536983)
7. Appel K, Honegger P, Gebicke-Haerter PJ (1995) Expression of interleukin-3 and tumor necrosis factor-beta mRNAs in cultured microglia. J Neuroimmunol 60:83-91
8. Araque A, Parpura V, Sanzgiri RP, Haydon PG (1999) Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 22:208-215 (Pubitemid 29202082)
9. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642 (Pubitemid 28443036)
10. Austin SA, Floden AM, Murphy EJ, Combs CK (2006) Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci 26:10558-10563 (Pubitemid 44564607)
11. Baba M, Nakajo S, Tu PH et al (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879-884 (Pubitemid 28173348)
12. Balasingam V, Dickson K, Brade A, Yong VW (1996) Astrocyte reactivity in neonatal mice: apparent dependence on the presence of reactive microglia/macrophages. Glia 18:11-26 (Pubitemid 26369597)
13. Baumann N, Pham-Dinh D (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871-927 (Pubitemid 32267079)
14. Becker C, Jick SS, Meier CR (2011) NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol. doi:10.1111/j.1468-1331.2011.03399.x
15. Benner EJ, Banerjee R, Reynolds AD et al (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3:e1376
16. Benner EJ, Mosley RL, Destache CJ et al (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101:9435-9440 (Pubitemid 38812892)
17. Beyer K, Ariza A (2007) Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J Neuropathol Exp Neurol 66:965-974 (Pubitemid 350060365)
18. Bianco F, Pravettoni E, Colombo A et al (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174:7268-7277 (Pubitemid 40705696)
19. Biju K, Zhou Q, Li G et al (2010) Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol Ther 18:1536-1544
20. Braak H, Del Tredici K (2004) Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 25:19-23 (Pubitemid 37522187)
21. Braak H, Del Tredici K (2009) Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 201:1-119
22. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann- Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249(Suppl 3):III/1-III/5
23. Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110:517-536 (Pubitemid 36543283)
24. Braak H, Sastre M, Del Tredici K (2007) Development of alphasynuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 114:231-241 (Pubitemid 47226149)
25. Bradl M, Lassmann H (2010) Oligodendrocytes: biology and pathology. Acta Neuropathol 119:37-53
26. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator- activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82:615-624 (Pubitemid 34831499)
27. Brochard V, Combadiere B, Prigent A et al (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192
28. Bundesen LQ, Scheel TA, Bregman BS, Kromer LF (2003) Ephrin-B2 and EphB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats. J Neurosci 23:7789-7800 (Pubitemid 37052347)
29. Bunge RP (1968) Glial cells and the central myelin sheath. Physiol Rev 48:197-251
30. Burke RE, Dauer WT, Vonsattel JP (2008) A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 64:485-491
31. Bush TG, Puvanachandra N, Horner CH et al (1999) Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23:297-308 (Pubitemid 29315725)
32. Bushong EA, Martone ME, Ellisman MH (2004) Maturation of astrocyte morphology and the establishment of astrocyte domains during postnatal hippocampal development. Int J Dev Neurosci 22:73-86 (Pubitemid 38264165)
33. Butt AM, Ibrahim M, Berry M (1998) Axon-myelin sheath relations of oligodendrocyte unit phenotypes in the adult rat anterior medullary velum. J Neurocytol 27:259-269 (Pubitemid 28416911)
34. Buttini M, Boddeke H (1995) Peripheral lipopolysaccharide stimulation induces interleukin-1 beta messenger RNA in rat brain microglial cells. Neuroscience 65:523-530
35. Calne DB, Mizuno Y (2004) The neuromythology of Parkinson's disease. Parkinsonism Relat Disord 10:319-322 (Pubitemid 38757814)
36. Campbell BC, McLean CA, Culvenor JG et al (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 76:87-96 (Pubitemid 32044371)
37. Carmignoto G, Gomez-Gonzalo M (2010) The contribution of astrocyte signalling to neurovascular coupling. Brain Res Rev 63:138-148
38. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yebenes J, Mena MA (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97:934-946
39. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123:383-396 (Pubitemid 41546670)
40. Choi DK, Pennathur S, Perier C et al (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 25:6594-6600 (Pubitemid 40995291)
41. Ciccarelli R, Ballerini P, Sabatino G et al (2001) Involvement of astrocytes in purine-mediated reparative processes in the brain. Int J Dev Neurosci 19:395-414 (Pubitemid 32500336)
42. Conde JR, Streit WJ (2006) Microglia in the aging brain. J Neuropathol Exp Neurol 65:199-203
43. Croisier E, Graeber MB (2006) Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol 112:517-530 (Pubitemid 44550676)
44. de Silva HR, Khan NL, Wood NW (2000) The genetics of Parkinson's disease. Curr Opin Genet Dev 10:292-298 (Pubitemid 30307248)
45. Dean JM, Wang X, Kaindl AM et al (2010) Microglial MyD88 signaling regulates acute neuronal toxicity of LPS-stimulated microglia in vitro. Brain Behav Immun 24:776-783
46. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88:494-501 (Pubitemid 38084565)
47. del Rio-Hortega P (1932) Microglia. In: Penfield W (ed) Cytology and cellular pathology of the nervous system. Hoeber PB, New York, pp 483-534
48. Dermietzel R, Gao Y, Scemes E et al (2000) Connexin43 null mice reveal that astrocytes express multiple connexins. Brain Res Brain Res Rev 32:45-56 (Pubitemid 30177309)
49. Deshpande M, Zheng J, Borgmann K et al (2005) Role of activated astrocytes in neuronal damage: potential links to HIV-1-associated dementia. Neurotox Res 7:183-192
50. Desplats P, Lee HJ, Bae EJ et al (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106:13010-13015
51. Dickson DW, Lin W, Liu WK, Yen SH (1999) Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 9:721-732 (Pubitemid 29470964)
52. Dodel R, Spottke A, Gerhard A et al (2010) Minocycline 1-year therapy inmultiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET(MEMSA-trial).MovDisord 25:97-107
53. Domercq M, Sanchez-Gomez MV, Sherwin C, Etxebarria E, Fern R, Matute C (2007) System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol 178:6549-6556 (Pubitemid 46717438)
54. Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384-386 (Pubitemid 46184217)
55. Durrenberger PF, Filiou MD, Moran LB et al (2009) DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in parkinsonian astrocytes. J Neurosci Res 87:238-245
56. Edwards TL, Scott WK, Almonte C et al (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74:97-109
57. Eklind S, Hagberg H, Wang X et al (2006) Effect of lipopolysaccharide on global gene expression in the immature rat brain. Pediatr Res 60:161-168 (Pubitemid 44297586)
58. El-Agnaf OM, Salem SA, Paleologou KE et al (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17:1945-1947
59. Elbaz A, Ross OA, Ioannidis JP et al (2010) Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol 69:778-792
60. Emmanouilidou E, Melachroinou K, Roumeliotis T et al (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30:6838-6851
61. Escartin C, Bonvento G (2008) Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol 38:231-241
62. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205:295-312 (Pubitemid 46778915)
63. Faissner A, Pyka M, Geissler M et al (2010) Contributions of astrocytes to synapse formation and maturation - potential functions of the perisynaptic extracellular matrix. Brain Res Rev 63:26-38
64. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283-2301
65. Flanary BE, Streit WJ (2003) Telomeres shorten with age in rat cerebellum and cortex in vivo. J Anti Aging Med 6:299-308 (Pubitemid 38580423)
66. Flanary BE, Streit WJ (2004) Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia 45:75-88 (Pubitemid 38076230)
67. Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74:995-1002
68. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM (2008) Neuroinflammation and oxidation/nitration of alphasynuclein linked to dopaminergic neurodegeneration. J Neurosci 28:7687-7698
69. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS (2011) HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31:1081-1092
70. Garcia-Matas S, Gutierrez-Cuesta J, Coto-Montes A et al (2008) Dysfunction of astrocytes in senescence-accelerated mice SAMP8 reduces their neuroprotective capacity. Aging Cell 7:630-640
71. Gerhard A, Banati RB, Goerres GB et al (2003) [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61:686-689 (Pubitemid 37082607)
72. Gerhard A, Pavese N, Hotton G et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404-412
73. Geser F, Jellinger KA, Köllensperger M, Stefanova N, Wenning GK (2010) Multiple system atrophy. Etiology, pathology, and pathogenesis. In: Schapira AHV, Lang AET, Fahn S (eds) Movement disorders 4. Elsevier, Saunders, pp 321-339
74. Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989
75. Gilman S, Low PA, Quinn N et al (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163:94-98 (Pubitemid 29155424)
76. Ginhoux F, Greter M, Leboeuf M et al (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330:841-845
77. Glanzer JG, Enose Y, Wang T et al (2007) Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation. J Neurochem 102:627-645 (Pubitemid 47057284)
78. Golgi C (1903) Opera Omnia. Hoepli, Milano
79. Gonzalez-Perez O, Alvarez-Buylla A (2011) Oligodendrogenesis in the subventricular zone and the role of epidermal growth factor. Brain Res Rev
80. Graeber MB, Streit WJ (2010) Microglia: biology and pathology. Acta Neuropathol 119:89-105
81. Greten-Harrison B, Polydoro M, Morimoto-Tomita M et al (2010) alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci USA 107:19573-19578
82. Gu XL, Long CX, Sun L, Xie C, Lin X, Cai H (2010) Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain 3:12
83. Halassa MM, Fellin T, Takano H, Dong JH, Haydon PG (2007) Synaptic islands defined by the territory of a single astrocyte. J Neurosci 27:6473-6477 (Pubitemid 46920364)
84. Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord 26:6-17
85. Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40:140-155
86. Hansen C, Angot E, Bergstrom AL et al (2011) alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121:715-725
87. Hasegawa-Ishii S, Takei S, Inaba M et al (2010) Defects in cytokine-mediated neuroprotective glial responses to excitotoxic hippocampal injury in senescence-accelerated mouse. Brain Behav Immun 25:83-100
88. Hashioka S, Klegeris A, Schwab C, McGeer PL (2009) Interferongamma- dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging 30:1924-1935
89. Hayakawa N, Kato H, Araki T (2007) Age-related changes of astorocytes, oligodendrocytes and microglia in the mouse hippocampal CA1 sector. Mech Ageing Dev 128:311-316 (Pubitemid 46590305)
90. Hayes GM, Woodroofe MN, Cuzner ML (1987) Microglia are the major cell type expressing MHC class II in human white matter. J Neurol Sci 80:25-37 (Pubitemid 17094622)
91. Heneka MT, Rodriguez JJ, Verkhratsky A (2010) Neuroglia in neurodegeneration. Brain Res Rev 63:189-211
92. Herrmann JE, Imura T, Song B et al (2008) STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci 28:7231-7243
93. Hines DJ, Hines RM, Mulligan SJ, Macvicar BA (2009) Microglia processes block the spread of damage in the brain and require functional chloride channels. Glia 57:1610-1618
94. Hirohata M, Ono K, Morinaga A, Yamada M (2008) Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Neuropharmacology 54:620-627
95. Hirsch EC, Hunot S, Hartmann A (2005) Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 11(Suppl 1):S9-S15 (Pubitemid 40693572)
96. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ (2000) Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 165:618-622 (Pubitemid 30484724)
97. Hlavanda E, Klement E, Kokai E et al (2007) Phosphorylation blocks the activity of tubulin polymerization-promoting protein (TPPP): identification of sites targeted by different kinases. J Biol Chem 282:29531-29539 (Pubitemid 350043337)
98. Hunter RL, Dragicevic N, Seifert K et al (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100:1375-1386
99. Ikeda K, Akiyama H, Kondo H et al (1995) Thorn-shaped astrocytes: possibly secondarily induced tau-positive glial fibrillary tangles. Acta Neuropathol 90:620-625
100. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63:43-52 (Pubitemid 38030232)
101. Iwai A, Masliah E, Yoshimoto M et al (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467-475
102. Jakel RJ, Townsend JA, Kraft AD, Johnson JA (2007) Nrf2- mediated protection against 6-hydroxydopamine. Brain Res 1144:192-201 (Pubitemid 46440842)
103. Jander S, Pohl J, D'Urso D, Gillen C, Stoll G (1998) Time course and cellular localization of interleukin-10 mRNA and protein expression in autoimmune inflammation of the rat central nervous system. Am J Pathol 152:975-982 (Pubitemid 28173359)
104. Jellinger KA (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18(Suppl 6):S2-S12
105. Jellinger KA (2007) Lewy body disorders. In: Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (eds) Degenerative diseases of the nervous system. Springer, New York, pp 267-343
106. Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792:730-740
107. Jellinger KA, Lantos PL (2010) Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 119:657-667
108. Jellinger KA, Seppi K, Wenning GK (2005) Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20(Suppl 12):S29-S36 (Pubitemid 41419552)
109. Jurewicz A, Matysiak M, Tybor K, Kilianek L, Raine CS, Selmaj K (2005) Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 128:2675-2688 (Pubitemid 41552951)
110. Juurlink BH (1997) Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. Neurosci Biobehav Rev 21:151-166
111. Kahle PJ, Neumann M, Ozmen L et al (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3:583-588 (Pubitemid 34752460)
112. Kandel ER (1991) Nerve cell and behavior. Principles of neural science. Elsevier, New York, pp 18-32
113. Kiefer R, Schweitzer T, Jung S, Toyka KV, Hartung HP (1998) Sequential expression of transforming growth factor-beta1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation. J Neuropathol Exp Neurol 57:385-395 (Pubitemid 28237322)
114. Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL (2006) Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 20:2000-2008 (Pubitemid 44953900)
115. Klegeris A, Pelech S, Giasson BI et al (2008) Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 29:739-752 (Pubitemid 351400820)
116. Knott C, Stern G, Kingsbury A, Welcher AA, Wilkin GP (2002) Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra. Parkinsonism Relat Disord 8:329-341 (Pubitemid 34518414)
117. Knox CA, Kokmen E, Dyck PJ (1989) Morphometric alteration of rat myelinated fibers with aging. J Neuropathol Exp Neurol 48:119-139 (Pubitemid 19073973)
118. Koehler RC, Roman RJ, Harder DR (2009) Astrocytes and the regulation of cerebral blood flow. Trends Neurosci 32:160-169
119. Kofuji P, Newman EA (2004) Potassium buffering in the central nervous system. Neuroscience 129:1045-1056 (Pubitemid 39556255)
120. Kong LY, McMillian MK, Hudson PM, Jin L, Hong JS (1997) Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. J Pharmacol Exp Ther 280:61-66 (Pubitemid 27171388)
121. Kragh CL, Lund LB, Febbraro F et al (2009) {alpha}-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284:10211-10222
122. Lasn H, Winblad B, Bogdanovic N (2006) Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease. J Cell Mol Med 10:145-156 (Pubitemid 44874297)
123. Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151-170
124. Lee HJ, Patel S, Lee SJ (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25:6016-6024 (Pubitemid 40911433)
125. Lee HJ, Suk JE, Bae EJ, Lee SJ (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 372:423-428
126. Lee HJ, Suk JE, Patrick C et al (2010) Direct transfer of alphasynuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285:9262-9272
127. Letiembre M, Liu Y, Walter S et al (2009) Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 30:759-768
128. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW (2004) Pro-regenerative properties of cytokine-activated astrocytes. J Neurochem 89:1092-1100 (Pubitemid 38715826)
129. Liddell JR, Robinson SR, Dringen R, Bishop GM (2010) Astrocytes retain their antioxidant capacity into advanced old age. Glia 58:1500-1509
130. Lien E, Means TK, Heine H et al (2000) Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 105:497-504 (Pubitemid 30127250)
131. Lindersson E, Lundvig D, Petersen C et al (2005) p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J Biol Chem 280:5703-5715 (Pubitemid 40280050)
132. Liu JS, Amaral TD, Brosnan CF, Lee SC (1998) IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J Immunol 161:1989-1996 (Pubitemid 28387624)
133. Long-Smith CM, Collins L, Toulouse A, Sullivan AM, Nolan YM (2010) Interleukin-1beta contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro. J Neuroimmunol 226:20-26
134. Lu L, Mak YT, Fang M, Yew DT (2009) The difference in gliosis induced by beta-amyloid and Tau treatments in astrocyte cultures derived from senescence accelerated and normal mouse strains. Biogerontology 10:695-710
135. Lu X, Bing G, Hagg T (2000) Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97:285-291 (Pubitemid 30224766)
136. Lynch MA (2009) The multifaceted profile of activated microglia. Mol Neurobiol 40:139-156
137. Mackenzie IR (2000) Activated microglia in dementia with Lewy bodies. Neurology 55:132-134
138. Maehlen J, Olsson T, Zachau A, Klareskog L, Kristensson K (1989) Local enhancement of major histocompatibility complex (MHC) class I and II expression and cell infiltration in experimental allergic encephalomyelitis around axotomized motor neurons. J Neuroimmunol 23:125-132 (Pubitemid 19144793)
139. Marks WJ Jr, Bartus RT, Siffert J et al (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164-1172
140. Marner L, Nyengaard JR, Tang Y, Pakkenberg B (2003) Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol 462:144-152 (Pubitemid 36723664)
141. Masliah E, Rockenstein E, Adame A et al (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46:857-868 (Pubitemid 40805347)
142. Matsuo A, Akiguchi I, Lee GC, McGeer EG, McGeer PL, Kimura J (1998) Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 153:735-744 (Pubitemid 28419028)
143. Matute C, Alberdi E, Domercq M et al (2007) Excitotoxic damage to white matter. J Anat 210:693-702
144. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291
145. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23:474-483
146. McKeith IG, Burn DJ, Ballard CG et al (2003) Dementia with Lewy bodies. Semin Clin Neuropsychiatry 8:46-57 (Pubitemid 36828251)
147. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124 (Pubitemid 26374873)
148. McTigue DM, Tripathi RB (2008) The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 107:1-19
149. Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm 112:1613-1624 (Pubitemid 41598967)
150. Mirza B, Hadberg H, Thomsen P, Moos T (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95:425-432
151. Mizuno T, Kuno R, Nitta A et al (2005) Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes. Brain Res 1066:78-85 (Pubitemid 41790731)
152. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230-240
153. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 176:98-104 (Pubitemid 34762109)
154. Nakamura K, Nemani VM, Azarbal F et al. (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein {alpha}-synuclein. J Biol Chem
155. Nave KA, Trapp BD (2008) Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 31:535-561
156. Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, Barde YA (2002) Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. J Neurosci 22:854-862 (Pubitemid 34141766)
157. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318 (Pubitemid 40746128)
158. Nishie M, Mori F, Fujiwara H et al (2004) Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 107:292-298 (Pubitemid 38477355)
159. Nishioka K, Hayashi S, Farrer MJ et al (2006) Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59:298-309 (Pubitemid 43202483)
160. Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ (2010) Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging (in press, corrected proof)
161. Norris EH, Giasson BI, Lee VM (2004) Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 60:17-54 (Pubitemid 39752358)
162. Norton WT, Aquino DA, Hozumi I, Chiu FC, Brosnan CF (1992) Quantitative aspects of reactive gliosis: a review. Neurochem Res 17:877-885
163. O'Sullivan SS, Massey LA, Williams DR et al (2008) Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131:1362-1372
164. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128:2665-2674 (Pubitemid 41552950)
165. Ozawa T, Okuizumi K, Ikeuchi T, Wakabayashi K, Takahashi H, Tsuji S (2001) Analysis of the expression level of alphasynuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol 102:188-190 (Pubitemid 32771668)
166. Ozawa T, Paviour D, Quinn NP et al (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657-2671 (Pubitemid 39627375)
167. Ozawa T, Takano H, Onodera O et al (1999) No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett 270:110-112 (Pubitemid 29333848)
168. Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79-100 (Pubitemid 20019446)
169. Papp MI, Lantos PL (1994) The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 117(Pt 2):235-243 (Pubitemid 24155496)
170. Park JY, Paik SR, Jou I, ParkSM(2008) Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alphasynuclein: implications for Parkinson's disease. Glia 56:1215-1223
171. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82-91 (Pubitemid 40053318)
172. Peters A (2002) Structural changes in the normally aging cerebral cortex of primates. Prog Brain Res 136:455-465
173. Polazzi E, Monti B (2010) Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol 92:293-315
174. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047 (Pubitemid 27443610)
175. Qian L, Flood PM (2008) Microglial cells and Parkinson's disease. Immunol Res 41:155-164
176. Qian L, Flood PM, Hong JS (2010) Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 117:971-979
177. Racette B (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31:141-150
178. Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW (1999) Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev 30:77-105 (Pubitemid 29331517)
179. Randy LH, Guoying B (2007) Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr Neuropharmacol 5:35-46
180. Rauen T, Taylor WR, Kuhlbrodt K, Wiessner M (1998) Highaffinity glutamate transporters in the rat retina: a major role of the glial glutamate transporter GLAST-1 in transmitter clearance. Cell Tissue Res 291:19-31 (Pubitemid 28081563)
181. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL (2007) Neuroprotective activities of CD4? CD25? regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 82:1083-1094 (Pubitemid 350133504)
182. Reynolds AD, Glanzer JG, Kadiu I et al (2008) Nitrated alphasynuclein- activated microglial profiling for Parkinson's disease. J Neurochem 104:1504-1525 (Pubitemid 351316759)
183. Reynolds AD, Kadiu I, Garg SK et al (2008) Nitrated alphasynuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol 3:59-74
184. Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM (2000) alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res 62:9-14
185. Riedel M, Goldbaum O, Richter-Landsberg C (2009) alpha- Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. J Mol Neurosci 39:226-234
186. Rohl C, Lucius R, Sievers J (2007) The effect of activated microglia on astrogliosis parameters in astrocyte cultures. Brain Res 1129:43-52 (Pubitemid 46048779)
187. Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E et al (2010) Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants. PLoS One 5:e13481
188. Ros-Bernal F, Hunot S, Herrero MT et al (2011) Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci USA 108:6632-6637
189. Rothstein JD, Dykes-Hoberg M, Pardo CA et al (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686 (Pubitemid 26103145)
190. Saavedra A, Baltazar G, Santos P, Carvalho CM, Duarte EP (2006) Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuronglia crosstalk. Neurobiol Dis 23:533-542 (Pubitemid 44234089)
191. Samii A, Etminan M, Wiens MO, Jafari S (2009) NSAID use and the risk of Parkinson's disease: systematic review and metaanalysis of observational studies. Drugs Aging 26:769-779
192. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 5:e8784
193. Sandhu JK, Gardaneh M, Iwasiow R et al (2009) Astrocytesecreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis 33:405-414
194. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116:1744-1754 (Pubitemid 44033293)
195. Schipper HM (2004) Brain iron deposition and the free radicalmitochondrial theory of ageing. Ageing Res Rev 3:265-301
196. Schmidt S, Linnartz B, Mendritzki S et al (2011) Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria. Hum Mol Genet 20:1197-1211
197. Scholz SW, Houlden H, Schulte C et al (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65:610-614
198. Schrag A, Ben-Shlomo Y, Quinn NP (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354:1771-1775
199. Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y (2008) Survival in multiple system atrophy. Mov Disord 23:294-296 (Pubitemid 351311566)
200. Schwartz JP, Nishiyama N (1994) Neurotrophic factor gene expression in astrocytes during development and following injury. Brain Res Bull 35:403-407 (Pubitemid 24342089)
201. Sheffield LG, Berman NE (1998) Microglial expression of MHC class II increases in normal aging of nonhuman primates. Neurobiol Aging 19:47-55 (Pubitemid 28167795)
202. Shimura H, Schlossmacher MG, Hattori N et al (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293:263-269 (Pubitemid 32694735)
203. Shults CW, Rockenstein E, Crews L et al (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 25:10689-10699 (Pubitemid 41681917)
204. Simard M, Nedergaard M (2004) The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 129:877-896 (Pubitemid 39556241)
205. Singleton AB, Farrer M, Johnson J et al (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841 (Pubitemid 37339619)
206. Sloane JA, Hinman JD, Lubonia M, Hollander W, Abraham CR (2003) Age-dependent myelin degeneration and proteolysis of oligodendrocyte proteins is associated with the activation of calpain-1 in the rhesus monkey. J Neurochem 84:157-168 (Pubitemid 36182076)
207. Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32:638-647
208. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:7-35
209. Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, Sasaki H (2006) Heredity in multiple system atrophy. J Neurol Sci 240:107-110 (Pubitemid 41814963)
210. Song YJ, Lundvig DM, Huang Y et al (2007) p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171:1291-1303 (Pubitemid 47582902)
211. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251:205-208 (Pubitemid 28381082)
212. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839-840
213. Stefanova N, Eriksson H, Georgievska B, Poewe W, Wenning GK (2010) Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Mov Disord 25(Suppl. 3):625
214. Stefanova N, Hainzer M, Stemberger S et al (2009) Striatal transplantation for multiple system atrophy - are grafts affected by alpha-synucleinopathy? Exp Neurol 219:368-371
215. Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M (2001) Glial cell death induced by overexpression of alphasynuclein. J Neurosci Res 65:432-438 (Pubitemid 32831396)
216. Stefanova N, Mitschnigg M, Ghorayeb I et al (2004) Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res 78:87-91 (Pubitemid 39305157)
217. Stefanova N, Reindl M, Neumann M et al (2005) Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166:869-876 (Pubitemid 40315643)
218. Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 22:2196-2203
219. Stefanova N, Schanda K, Klimaschewski L, Poewe W, Wenning GK, Reindl M (2003) Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. J Neurosci Res 73:334-340 (Pubitemid 36918097)
220. Stefanova N, Stemberger S, Fellner L et al (2010) Disturbance of innate immunity linked to toll-like receptor 4 promotes neurodegeneration in a transgenic alpha-synucleinopathy model. Mov Disord 25(Suppl. 2):210-211
221. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK (2005) Animal models of multiple system atrophy. Trends Neurosci 28:501-506 (Pubitemid 41187800)
222. Stemberger S, Poewe W, Wenning GK, Stefanova N (2010) Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp Neurol 224:459-464
223. Stoll G, Jander S (1999) The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 58:233-247
224. Streit WJ (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40:133-139
225. Streit WJ (2004) Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 77:1-8
226. Streit WJ, Sammons NW, Kuhns AJ, Sparks DL (2004) Dystrophic microglia in the aging human brain. Glia 45:208-212 (Pubitemid 38196997)
227. Su X, Federoff HJ, Maguire-Zeiss KA (2009) Mutant alphasynuclein overexpression mediates early proinflammatory activity. Neurotox Res 16:238-254
228. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29:1690-1701
229. Sugiyama I, Tanaka K, Akita M, Yoshida K, Kawase T, Asou H (2002) Ultrastructural analysis of the paranodal junction of myelinated fibers in 31-month-old-rats. J Neurosci Res 70:309-317 (Pubitemid 35222366)
230. Takahashi M, Tomizawa K, Fujita SC, Sato K, Uchida T, Imahori K (1993) A brain-specific protein p25 is localized and associated with oligodendrocytes, neuropil, and fiber-like structures of the CA3 hippocampal region in the rat brain. J Neurochem 60:228-235 (Pubitemid 23006722)
231. Tanaka J, Maeda N (1996) Microglial ramification requires nondiffusible factors derived from astrocytes. Exp Neurol 137:367-375 (Pubitemid 26080333)
232. Tanaka J, Okuma Y, Tomobe K, Nomura Y (2005) The age-related degeneration of oligodendrocytes in the hippocampus of the senescence-accelerated mouse (SAM) P8: a quantitative immunohistochemical study. Biol Pharm Bull 28:615-618 (Pubitemid 40879925)
233. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510-518
234. Taylor DL, Pirianov G, Holland S et al (2010) Attenuation of proliferation in oligodendrocyte precursor cells by activated microglia. J Neurosci Res 88:1632-1644
235. Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39:167-174 (Pubitemid 32104022)
236. Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67:1149-1158
237. Thorburne SK, Juurlink BH (1996) Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem 67:1014-1022 (Pubitemid 26277913)
238. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR (2009) Oligodendrocytes and myelination: the role of iron. Glia 57:467-478
239. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 278:44405-44411 (Pubitemid 37377190)
240. Togo T, Dickson DW (2002) Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Acta Neuropathol 104:398-402 (Pubitemid 36075405)
241. Trojanowski JQ, Revesz T (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33:615-620 (Pubitemid 350076093)
242. Tsuboi K, Grzesiak JJ, Bouvet M, Hashimoto M, Masliah E, Shults CW (2005) Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death. Mol Cell Neurosci 29:259-268 (Pubitemid 40725616)
243. Ubhi K, Rockenstein E, Mante M et al (2010) Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 30:6236-6246
244. van Rossum D, Hanisch UK (2004) Microglia. Metab Brain Dis 19:393-411
245. Verkhratsky A, Kettenmann H (1996) Calcium signalling in glial cells. Trends Neurosci 19:346-352 (Pubitemid 26349064)
246. Vila M, Jackson-Lewis V, Guegan C et al (2001) The role of glial cells in Parkinson's disease. Curr Opin Neurol 14:483-489 (Pubitemid 32703541)
247. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 99:14-20 (Pubitemid 30093433)
248. Wakabayashi K, Takahashi H (2006) Cellular pathology in multiple system atrophy. Neuropathology 26:338-345 (Pubitemid 44086838)
249. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180-182 (Pubitemid 28331545)
250. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J (2009) Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 29:3974-3980
251. Wang X, Zhu S, Drozda M et al (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 100:10483-10487 (Pubitemid 37071904)
252. Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE (1994) "Minimal change" multiple system atrophy. Mov Disord 9:161-166
253. Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG (2008) Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64:239-246
254. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12:133-147 (Pubitemid 27152018)
255. Wilhelmsson U, Bushong EA, Price DL et al (2006) Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc Natl Acad Sci USA 103:17513-17518 (Pubitemid 44789000)
256. Wu DC, Jackson-Lewis V, Vila M et al (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl- 1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771
257. Wullner U, Schmitt I, Kammal M, Kretzschmar HA, Neumann M (2009) Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 80:449-450
258. Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 84:100-104
259. Yamada T, McGeer PL, McGeer EG (1992) Some immunohistochemical features of argyrophilic grain dementia with normal cortical choline acetyltransferase levels but extensive subcortical pathology and markedly reduced dopamine. J Geriatr Psychiatry Neurol 5:3-13
260. Yao SY, Ljunggren-Rose A, Chandramohan N, Whetsell WO Jr, Sriram S (2010) In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes. J Neuroimmunol 229:146-156
261. Yazawa I, Giasson BI, Sasaki R et al (2005) Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847-859 (Pubitemid 40395264)
262. Zarranz JJ, Alegre J, Gomez-Esteban JC et al (2004) The new mutation, E46 K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173 (Pubitemid 38166992)
263. Zhang W, Wang T, Pei Z et al (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:533-542 (Pubitemid 40471244)
264. Zhang X, Haaf M, Todorich B et al (2005) Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 52:199-208 (Pubitemid 43078509)